Tandem Diabetes Care Reports Q3 2025 Revenue of $249.3 Million, Net Loss of $21.2 Million

Tandem Diabetes Care, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a total revenue of $249.3 million for the quarter, a slight increase from $244.0 million in the same period last year. For the nine months ended September 30, 2025, revenue reached $724.4 million, compared to $657.6 million for the same period in 2024. The company experienced a gross profit of $134.3 million for the third quarter, resulting in a gross margin of 54%, up from 51% in the prior year. However, Tandem reported a net loss of $21.2 million for the quarter, a decrease from a loss of $23.3 million in Q3 2024, and a net loss of $204.1 million for the nine months, significantly higher than the $96.8 million loss reported in the same period last year.

The company’s operational metrics showed a total of approximately 30,000 pumps shipped worldwide during the third quarter, with U.S. sales contributing $175.6 million, while international sales accounted for $73.6 million. The increase in sales was attributed to improved average selling prices across all products, although pump shipments slightly decreased. The company also noted that sales outside the U.S. benefited from favorable foreign exchange rates and higher supply volumes, despite a decline in pump volumes due to distributor destocking in anticipation of direct sales activities set to begin in early 2026.

Tandem Diabetes Care has been actively expanding its product offerings, including the recent launch of the Tandem Mobi insulin pump, which is designed to be smaller and more discreet than its predecessor, the t:slim X2. The company received CE Mark approval for the Tandem Mobi in May 2025 and is pursuing additional regulatory approvals for international markets. The company’s strategic focus includes enhancing its product portfolio and expanding its market presence, particularly in the U.S. and Europe, where it plans to initiate direct sales in select countries.

Financially, Tandem's total assets decreased to $874.7 million as of September 30, 2025, down from $967.7 million at the end of 2024. The company’s cash and cash equivalents increased to $91.9 million, while short-term investments decreased to $227.2 million. The company’s liabilities also rose, totaling $741.7 million, compared to $704.6 million at the end of 2024. The increase in liabilities was primarily due to the company’s ongoing investments in product development and expansion efforts.

Looking ahead, Tandem Diabetes Care anticipates continued fluctuations in its financial performance due to various factors, including market acceptance of its products, regulatory approvals, and competitive pressures. The company is focused on maintaining its growth trajectory while managing its operational costs and enhancing its product offerings to meet the evolving needs of insulin-dependent diabetes patients.